Total Valuation
Ryvu Therapeutics SA has a market cap or net worth of €84.27M. The enterprise value is €318.33.
Market Cap€84.27M
Enterprise Value€318.33
Share Statistics
Ryvu Therapeutics SA has 23,120,148 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding23,120,148
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Ryvu Therapeutics SA’s return on equity (ROE) is -1.88 and return on invested capital (ROIC) is -74.78%.
Return on Equity (ROE)-1.88
Return on Assets (ROA)-0.45
Return on Invested Capital (ROIC)-74.78%
Return on Capital Employed (ROCE)-0.75
Revenue Per Employee273.04K
Profits Per Employee-443.99K
Employee Count228
Asset Turnover0.28
Inventory Turnover134.30
Valuation Ratios
The current PE Ratio of Ryvu Therapeutics SA is ―. Ryvu Therapeutics SA’s PEG ratio is 0.68.
PE Ratio―
PS Ratio10.06
PB Ratio11.64
Price to Fair Value11.64
Price to FCF-5.32
Price to Operating Cash Flow-4.53
PEG Ratio0.68
Income Statement
In the last 12 months, Ryvu Therapeutics SA had revenue of 62.25M and earned -101.23M in profits. Earnings per share was -4.38.
Revenue62.25M
Gross Profit-117.03M
Operating Income-122.15M
Pretax Income-101.14M
Net Income-101.23M
EBITDA-112.71M
Earnings Per Share (EPS)-4.38
Cash Flow
In the last 12 months, operating cash flow was -76.54M and capital expenditures -7.21M, giving a free cash flow of -83.75M billion.
Operating Cash Flow-76.54M
Free Cash Flow-83.75M
Free Cash Flow per Share-3.62
Dividends & Yields
Ryvu Therapeutics SA pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.50
52-Week Price Change-45.51%
50-Day Moving Average3.66
200-Day Moving Average4.74
Relative Strength Index (RSI)37.74
Average Volume (3m)32.00
Important Dates
Ryvu Therapeutics SA upcoming earnings date is Nov 5, 2026, TBA (Confirmed).
Last Earnings DateSep 17, 2026
Next Earnings DateNov 5, 2026
Ex-Dividend Date―
Financial Position
Ryvu Therapeutics SA as a current ratio of 2.26, with Debt / Equity ratio of 264.11%
Current Ratio2.26
Quick Ratio2.24
Debt to Market Cap0.11
Net Debt to EBITDA-0.11
Interest Coverage Ratio-13.88
Taxes
In the past 12 months, Ryvu Therapeutics SA has paid 88.00K in taxes.
Income Tax88.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Ryvu Therapeutics SA EV to EBITDA ratio is -5.67, with an EV/FCF ratio of -5.42.
EV to Sales10.26
EV to EBITDA-5.67
EV to Free Cash Flow-5.42
EV to Operating Cash Flow-5.79
Balance Sheet
Ryvu Therapeutics SA has €74.74M in cash and marketable securities with €74.94M in debt, giving a net cash position of -€198.00K billion.
Cash & Marketable Securities€74.74M
Total Debt€74.94M
Net Cash-€198.00K
Net Cash Per Share>-€0.01
Tangible Book Value Per Share€2.80
Margins
Gross margin is -48.97%, with operating margin of -196.22%, and net profit margin of -162.61%.
Gross Margin-48.97%
Operating Margin-196.22%
Pretax Margin-162.47%
Net Profit Margin-162.61%
EBITDA Margin-181.05%
EBIT Margin-196.22%
Analyst Forecast
The average price target for Ryvu Therapeutics SA is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-11.09%
EPS Growth Forecast43.34%